(211 days)
Not Found
No
The summary describes an automated system for microbial identification and susceptibility testing based on biochemical reactions and turbidity/redox indicator changes. It does not mention any AI or ML components in its description or performance evaluation.
No
The device is described as an in vitro diagnostic (IVD) system used for the rapid identification and antimicrobial susceptibility testing of bacterial isolates, not for direct treatment or diagnosis of a patient's condition.
Yes
The device is intended for the rapid identification and antimicrobial susceptibility testing of bacterial isolates of human origin, which are diagnostic purposes for identifying pathogens and determining effective treatments.
No
The device description explicitly lists hardware components such as the "BD Phoenix instrument" and "BD Phoenix panels," in addition to the software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the system is intended for "in vitro antimicrobial susceptibility testing of isolates from pure culture of most aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria of human origin." and "in vitro quantitative determination of antimicrobial susceptibility". The addition of the confirmatory ESBL Test is also described as a "confirmatory test for the detection of the organisms that produce extended spectrum 3-lactamses (ESBL)". These descriptions clearly indicate that the device is used to perform tests on biological samples (bacterial isolates) outside of the human body to provide diagnostic information.
- Device Description: The description details the components and how the system works to identify and perform susceptibility testing on bacterial isolates. This process involves analyzing the growth of bacteria in the presence of reagents and antimicrobial agents, which is a characteristic function of an in vitro diagnostic device.
- Performance Studies: The document describes performance studies comparing the Phoenix System results to reference methods and expected results, which is a standard requirement for demonstrating the accuracy and reliability of an IVD.
- Predicate Devices: The listed predicate devices (Sensititre® ESBL confirmatory test plate and previous versions of the BD Phoenix™ Automated Microbiology System) are also IVDs, further supporting the classification of this device as an IVD.
The core function of the BD Phoenix™ Automated Microbiology System, as described, is to perform diagnostic tests on biological samples (bacterial isolates) in a laboratory setting to aid in the diagnosis and treatment of infections. This aligns perfectly with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The BD Phoenix™ Automated Microbiology System is intended for the rapid identification and in vitro antimicrobial susceptibility testing of isolates from pure culture of most aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria of human origin.
The BD Phoenix™ Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anacrobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus and Enterococcus.
This premarket notification is for the addition of the confirmatory ESBL Test to Gram-negative ID/AST or AST only Phoenix panels. The Phoenix confirmatory ESBL Test is a confirmatory test for the detection of the organisms that produce extended spectrum 3-lactamses (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca.
Product codes (comma separated list FDA assigned to the subject device)
LON
Device Description
The BD Phoenix Automated Microbiology System (Phoenix System) is an automated system for the rapid identification (ID) and antimicrobial susceptibility testing (AST) of clinically relevant bacterial isolates. The system includes the following components:
- BD Phoenix instrument and software. .
- BD Phoenix panels containing biochemicals for organism ID testing and antimicrobial . agents for AST determinations.
- BD Phoenix ID Broth used for performing ID tests and preparing AST Broth inoculum. .
- BD Phoenix AST Broth used for performing AST tests only. .
- BD Phoenix AST Indicator solution added to the AST Broth to aid in bacterial growth . determination.
The Phoenix panel is a sealed and self-inoculating molded polystyrene tray with 136 micro-wells containing dried reagents. Organisms for susceptibility testing must be a pure culture and preliminarily identified as a Gram-negative or Gram-positive isolate. For each isolate, an inoculation equivalent to a 0.5 McFarland standard is prepared in Phoenix ID Broth.
The Phoenix AST method is a broth based microdilution test. The Phoenix System utilizes a redox indicator for the detection of organism growth in the presence of an antimicrobial agent. Measurements of changes to the indicator as well as bacterial turbidity are used in the determination of bacterial growth. Each AST panel configuration contains several antimicrobial agents with a wide range of two-fold doubling dilution concentrations.
The instrument houses the panels where they are continuously incubated at a nominal temperature of 35°C. The instrument takes readings of the panels every 20 minutes. The readings are interpreted to give an identification of the isolate, minimum inhibitory concentration (MIC) values and category interpretations, S. I, or R (sensitive, intermediate, or resistant).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Site Reproducibility: Intra- and inter-site reproducibility of this antimicrobial agent in the BD Phoenix System was evaluated at three sites using a panel of Gram-negative isolates. Each site tested the isolates in triplicate on three different days using one lot of Gram-negative Phoenix panels containing this test and associated reagents.
Clinical Studies: Clinical, stock and challenge isolates were tested across multiple geographically diverse sites across the United States to demonstrate the performance of the Phoenix antimicrobial susceptibility test with the Gram-negative Phoenix panel format containing this test. Phoenix System results for Challenge set isolates were compared to the expected results. Phoenix System results for clinical isolates were compared to the results obtained from the NCCLS reference broth microdilution method.
Confirmatory ESBL Test Performance: Accuracy testing performed at multiple sites using Clinical and Challenge isolates. The results from the ESBL test resident on the Phoenix panels were compared to the results obtained from the reference confirmatory ESBL test. For Challenge organisms this result is an expected result and for Clinical isolates this result was obtained from concurrent testing in the NCCLS reference broth microdilution method. Additionally, a challenge set of 30 previously characterized organisms was tested at one site.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Site Reproducibility:
The results of the study demonstrate for the this test there was an overall intra-site reproducibility of greater than 90% and an overall inter-site reproducibility greater than 95% for the Gram-negative isolates tested.
Confirmatory ESBL Test Performance:
Positive Percent Agreement = 183/189 = 96.8%
Negative Percent Agreement = 780/812 = 96.1%
Overall Percent Agreement = 963/1001 = 96.2%
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Positive Percent Agreement = 96.8%
Negative Percent Agreement = 96.1%
Overall Percent Agreement = 96.2%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K031545, K020321, K020323, K020322
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.
(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
0
K033458
| MAY 2 8 2004 | 510(K) SUMMARY |
|---|---|
| SUBMITTED BY: | Becton, Dickinson and Company |
| 7 Loveton Circle | |
| Sparks, MD 21152 | |
| Phone: (410) 316-4287 | |
| Fax: 410-316-4499 | |
| CONTACT NAME: | Monica Evelyn Giguere |
| Regulatory Affairs Specialist | |
| DATE PREPARED: | May 27, 2004 |
| DEVICE TRADE NAME: | BD Phoenix™ Automated Microbiology System - |
| confirmatory ESBL Test | |
| DEVICE COMMON NAME: | Antimicrobial susceptibility test system-short incubation |
| DEVICE CLASSIFICATION: | Fully Automated Short-Term Incubation Cycle |
| Antimicrobial Susceptibility Device, 21 CFR 866.1645 | |
| PREDICATE DEVICES: | Sensititre® ESBL confirmatory test plate (K031545) and |
| BD Phoenix™ Automated Microbiology System with | |
| Gatifloxacin (K020321, May 23, 2002), Ofloxacin | |
| (K020323, April 14, 2002), and Levofloxacin (K020322, | |
| March 27, 2002). | |
| INTENDED USE: | The BD Phoenix™ Automated Microbiology System is |
| intended for the rapid identification and in vitro | |
| antimicrobial susceptibility testing of isolates from pure | |
| culture of most aerobic and facultative anaerobic Gram- | |
| negative and Gram-positive bacteria of human origin. |
1
DEVICE DESCRIPTION:
The BD Phoenix Automated Microbiology System (Phoenix System) is an automated system for the rapid identification (ID) and antimicrobial susceptibility testing (AST) of clinically relevant bacterial isolates. The system includes the following components:
- BD Phoenix instrument and software. .
- BD Phoenix panels containing biochemicals for organism ID testing and antimicrobial . agents for AST determinations.
- BD Phoenix ID Broth used for performing ID tests and preparing AST Broth inoculum. .
- BD Phoenix AST Broth used for performing AST tests only. .
- BD Phoenix AST Indicator solution added to the AST Broth to aid in bacterial growth . determination.
The Phoenix panel is a sealed and self-inoculating molded polystyrene tray with 136 micro-wells containing dried reagents. Organisms for susceptibility testing must be a pure culture and preliminarily identified as a Gram-negative or Gram-positive isolate. For each isolate, an inoculation equivalent to a 0.5 McFarland standard is prepared in Phoenix ID Broth.
The Phoenix AST method is a broth based microdilution test. The Phoenix System utilizes a redox indicator for the detection of organism growth in the presence of an antimicrobial agent. Measurements of changes to the indicator as well as bacterial turbidity are used in the determination of bacterial growth. Each AST panel configuration contains several antimicrobial agents with a wide range of two-fold doubling dilution concentrations.
The instrument houses the panels where they are continuously incubated at a nominal temperature of 35°C. The instrument takes readings of the panels every 20 minutes. The readings are interpreted to give an identification of the isolate, minimum inhibitory concentration (MIC) values and category interpretations, S. I, or R (sensitive, intermediate, or resistant).
DEVICE COMPARISON:
The BD Phoenix™ Automated Microbiology System demonstrated substantially equivalent performance when compared with the NCCLS reference broth microdilution method. This premarket notification provides data supporting the use of the BD Phoenix™ Automated Microbiology System Gram-negative ID/AST or AST only Phoenix panels with the confirmatory ESBL test.
SUMMARY OF SUBSTANTIAL EQUIVALENCE TESTING:
The BD Phoenix™ Automated Microbiology System has demonstrated substantially equivalent performance when compared to the NCCLS reference broth microdilution method (AST panels prepared according to NCCLS M7).
2
Site Reproducibility
Intra- and inter-site reproducibility of this antimicrobial agent in the BD Phoenix System was evaluated at three sites using a panel of Gram-negative isolates. Each site tested the isolates in triplicate on three different days using one lot of Gram-negative Phoenix panels containing this test and associated reagents.
The results of the study demonstrate for the this test there was an overall intra-site reproducibility of greater than 90% and an overall inter-site reproducibility greater than 95% for the Gram-negative isolates tested.
Clinical Studies
Clinical, stock and challenge isolates were tested across multiple geographically diverse sites across the United States to demonstrate the performance of the Phoenix antimicrobial susceptibility test with the Gram-negative Phoenix panel format containing this test. Phoenix System results for Challenge set isolates were compared to the expected results. Phoenix System results for clinical isolates were compared to the results obtained from the NCCLS reference broth microdilution method.
Confirmatory ESBL Test Performance
To determine the accuracy of the Phoenix Confirmatory ESBL test, accuracy testing was performed at multiple sites using Clinical and Challenge isolates. The results from the ESBL test resident on the Phoenix panels were compared to the results obtained from the reference confirmatory ESBL test.
For Challenge organisms this result is an expected result and for Clinical isolates this result was obtained from concurrent testing in the NCCLS reference broth microdilution method. Additionally, a challenge set of 30 previously characterized organisms was tested at one site.
Positive Percent Agreement = 183/189 = 96.8% Negative Percent Agreement = 780/812 = 96.1% Overall Percent Agreement = 963/1001 = 96.2%
3
Conclusions Drawn from Substantial Equivalence Studies
The data collected from the substantial equivalence studies demonstrate that testing on the BD Phoenix™ Automated Microbiology System with this test is substantially equivalent. Technological characteristics of this system are substantially equivalent to those used in the Sensititre® ESBL confirmatory test plates, which received clearance by the FDA under K031545 and BD Phoenix™ Automated Microbiology System with Gatifloxacin (K020321, May 23, 2002), Ofloxacin (K020323, April 14, 2002), and Levofloxacin (K020322, March 27, 2002).
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its body and wing. The eagle is positioned to the right of the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA", which is arranged in a circular fashion around the left side of the logo.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAY 2 8 2004
Ms. Monica E. Giguere Regulatory Affairs Specialist BD Diagnostics Systems Becton, Dickinson and Company 7 Loveton Circle Sparks, MD 21152
K033458 Re: Trade/Device Name: BD Phoenix™ Automated Microbiology System Confirmatory ESBL Test Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices Regulatory Class: Class II Product Code: LON Dated: April 6, 2004 Received: April 7, 2004
Dear Ms. Giguere:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (sec above) into cither class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
5
Page 2
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97), You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincercly yours.
Sagahts
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Page 1 of 1
510(k) Number: K033458
Device Name: BD Phoenix™ Automated Microbiology System for use with the confirmatory ESBL Test - Gram-negative ID/AST or AST only Phoenix panels.
Indications for Use:
The BD Phoenix™ Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anacrobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus and Enterococcus.
This premarket notification is for the addition of the confirmatory ESBL Test to Gram-negative ID/AST or AST only Phoenix panels. The Phoenix confirmatory ESBL Test is a confirmatory test for the detection of the organisms that produce extended spectrum 3-lactamses (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca.
Prescription Use V (Part 21 CFR 801 Subpart D) AND/OR
Over-the-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
SAKWA
Division Siging
Office of the Millettral Diginostic Device Evaratizitation rath Safety
510(k) $\frac{K03245K}{}$